Mr. Suk is an experienced executive within Canada’s pharmaceutical and healthcare industries. After holding senior executive roles at
“I deeply appreciate the value of healthcare innovation emanating from Covalon’s talented R&D lab and am therefore honoured to serve on the Board,” said Mr. Suk. “Covalon has succeeded in extremely competitive international markets and I see many further opportunities for growth in the coming years. I look forward to contributing and being part of Covalon’s continued success.”
“I am delighted to have Mr. Suk join Covalon’s Board of Directors,” said
Mr. Suk’s appointment to Covalon’s Board of Directors is subject to TSX approval.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including completion of integration of the AquaGuard acquisition, the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.